Alpha1-Antitrypsin Deficiency Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis
The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran affects the body (called pharmacodynamics), to learn if fazirsiran reduces other liver injury (inflammation) and the abnormal Z-AAT protein in the liver, to get information on how the body processes fazirsiran (called pharmacokinetics), to test how well fazirsiran works compared with a placebo in improving measures of liver scarring including imaging and liver biomarkers (substances in the blood that the body normally makes and help show if liver function is improving, staying the same, or getting worse) as well as to check for side effects in participants treated with fazirsiran compared with those who received placebo. Participants will either receive fazirsiran or placebo. Liver biopsies, a way of collecting a small tissue sample from the liver, will be taken twice during this study.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02282527 -
A Study to Assess Safety and PK of Liquid Alpha1-Proteinase Inhibitor (Human) in Treating Alpha1-Antitrypsin Deficiency
|
Phase 2/Phase 3 | |
| Terminated |
NCT02722304 -
Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency
|
Phase 3 | |
| Withdrawn |
NCT04440488 -
ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study
|
Phase 4 | |
| Completed |
NCT02525861 -
GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study
|
Phase 3 | |
| Recruiting |
NCT06165341 -
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
|
Phase 3 | |
| Completed |
NCT00157092 -
Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency
|
Phase 1/Phase 2 | |
| Terminated |
NCT00313144 -
Aralast alpha1-proteinase Inhibitor Surveillance Study
|
Phase 4 | |
| Completed |
NCT01651351 -
GLASSIA Infusion Rate Study
|
Phase 4 | |
| Completed |
NCT02870309 -
Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency
|
Phase 1/Phase 2 | |
| Completed |
NCT02870348 -
Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)
|
Phase 1/Phase 2 | |
| Completed |
NCT04474197 -
Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype
|
Phase 2 | |
| Completed |
NCT00161707 -
Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT05466747 -
A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema
|
Phase 4 | |
| Enrolling by invitation |
NCT05899673 -
An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease
|
Phase 3 | |
| Recruiting |
NCT04722887 -
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02929940 -
Liver Disease in Patients With alpha1-antitrypsin Deficiency
|
N/A |